Homepage > Company > Media > Pharma News > 2025 > PVRI Congress

PVRI Congress

Gossamer Bio showcases seralutinib seralutinib Clinical and Preclinical studies at PVRI Congress

SAN DIEGO - Gossamer Bio, Inc., a biopharmaceutical company in the clinical stage with a market capitalization of $225 million, has shared new research findings on its drug candidate seralutinib, at the recent Pulmonary Vascular Research Institute (PVRI) 2025 Annual Congress in Rio de Janeiro, Brazil.

The company's stock has shown strong momentum, gaining nearly 9% in the past week. According to InvestingPro analysis, the company maintains a healthy financial position with liquid assets exceeding short-term obligations.

The event, which took place from January 29th to February 1st, featured an oral presentation and three posters detailing the potential benefits of seralutinib in treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

The presented studies included preclinical models indicating that seralutinib may work synergistically with another drug, sotatercept, in treating PAH. Additionally, a post-hoc analysis of the TORREY open-label extension study suggested sustained benefits of seralutinib treatment. Another poster reported a sustained effect of the drug on circulating biomarkers in the TORREY Phase 2 open-label extension study. With a strong current ratio of 6.74, InvestingPro data suggests the company is well-positioned to continue its research programs. Five analysts have recently revised their earnings expectations upward, reflecting growing confidence in the company's pipeline.

Gossamer Bio aims to become a leader in the treatment of pulmonary hypertension and improve the lives of patients affected by this condition. Seralutinib, an inhaled PDGFR, CSF1R, and c-KIT inhibitor, is central to the company's development efforts in this therapeutic area. While the company is currently operating at a loss, InvestingPro analysis indicates the stock is trading below its Fair Value, potentially presenting an opportunity for investors interested in clinical-stage biotech companies.

Read also

UK and US agree on landmark pharma pricing tariff deal

The UK and US have agreed to keep tariffs on UK pharmaceutical shipments into the US at zero.

Parkinson's drug as basis for new anti-infectives

Pseudomonas aeruginosa – one of the most common hospital germs – has sophisticated mechanisms to efficiently infect the human body and evade the immune system or antibiotics.

Modified herpes virus helps destroy glioblastoma in preclinical models

Researchers at Mass General Brigham have modified a herpes simplex virus (HSV-1) that stimulates the immune system to attack glioblastoma cells.

Curi Bio: $10 Million Series B Closed To Scale Human-Relevant Preclinical Platforms

Curi Bio has secured a $10 million Series B round led by Seoul-based contract research organization DreamCIS, funding that will accelerate the expansion of the company’s integrated human-relevant pr...